Although it is generally assumed that prolonged childhood exposure to passive smoke may affect adult cardiovascular (CV) health, there are few studies of cardiac function decades after the exposure. Subclinical left ventricular dysfunction detected by GLS is predictive of the subsequent development of heart failure and was used as a surrogate for increased risk. The investigators addressed the association of passive smoke exposure during childhood with GLS in adulthood.
Dr Chigozie Ezegbe (University of Tasmania, Australia) presented the data, derived from the Childhood Determinants of Adult Health Study 34-year follow-up (2014â2019). From a validated questionnaire, results of 3 measures of passive smoke exposure were analysed: the severity of exposure index, the cumulative years of exposure, and the total number of household smokers. Linear regression analysis was adjusted for confounding factors (i.e. age, gender, childhood socioeconomic position, childhood smoking, adult smoking status, and parental education level). The mean age of participants was 45.2 years, and 55.4% were female. Of 781 participants, 54.2% had been exposed to passive smoking.
Per standard deviation (SD) of severity of exposure index, the GLS decreased (range 0â318; mean 24.2 ±35.8; ÎČ-adjusted -0.17%; 95% CI -0.32 to -0.02). Likewise, the cumulative years of exposure (range 0â106, mean 10.4 ±13.9) was associated with a decrease in GLS (ÎČ-adjusted -0.18%; -0.33 to -0.05) per SD of exposure. For each household smoker (range 0-5; mean 0.9 ±1.0), the GLS decreased as well (ÎČ-adjusted -0.20%; -0.36 to -0.05). Each 1% decrease in GLS was associated with a 12% higher risk of CV morbidity and mortality in a low-risk general population. Every effort should be made to prevent exposure of children to passive smoking during childhood due to potential long-term consequences to cardiac function.
- Ezegbe C, et al. Childhood Passive Smoke Exposure is Associated With Subclinical Left Ventricular Dysfunction in Adulthood â Childhood Determinants of Adult Health Study. P1917, AHA Scientific Sessions 2020, 13-17 Nov.
Posted on
Previous Article
« Transgender people have unaddressed heart disease risks Next Article
Mavacamten effective in obstructive hypertrophic cardiomyopathy »
« Transgender people have unaddressed heart disease risks Next Article
Mavacamten effective in obstructive hypertrophic cardiomyopathy »
Table of Contents: AHA 2020
Featured articles
COVID-19 and Influenza
Fewer CV complications than expected in AHA COVID-19 Registry
Worse COVID-19 outcomes in younger obese patients
Effects of CVD in hospitalised COVID-19 patients
Unfavourable outcomes for COVID-19 patients with AF and atrial flutter
High-dose influenza vaccine in patients with CVD
Atrial Fibrillation
Vitamin D or omega 3 fatty acids do not prevent AF
Active screening for AF improves clinical outcomes
AF screening in older adults at primary care visits
CVD Risk Reduction
Clever trial design gets patients back on statins: the SAMSON trial
Polypill plus aspirin reduces cardiovascular events
Lowering LDL cholesterol in older patients is beneficial
No CV benefit from omega 3 in high-risk patients
Safety and efficacy of inclisiran for hypercholesterolemia
Remote risk management programme effective and efficient
Healthy lifestyle lowers mortality irrespective of medication burden
Heart Failure
Omecamtiv mecarbil improves outcomes in HFrEF-patients
IV iron reduces HF hospitalisation
Dapagliflozin reduces renal risk independent of CV disease status
âStrongly consider an SGLT2-inhibitor in most T2DM patientsâ
Additional HFrEF education and patient-engagement tools
Acute Coronary Syndrome
No benefit from omega-3 fatty acids after recent MI
PIONEER III trial: Drug-eluting stents comparable
Coronary and Valve Disease
Extra imaging reveals cause of MINOCA in women
Ticagrelor not superior to clopidogrel after elective PCI
Stroke
Ticagrelor/aspirin reduces stroke risk in patients with ipsilateral cervicocranial plaque
AF monitoring following cardiovascular surgery
Miscellaneous
PAD: Rivaroxaban reduces VTE risk after revascularisation
Sotatercept: potential new treatment option for PAH
Finerenone lowers CV events in diabetic CKD patients
Mavacamten effective in obstructive hypertrophic cardiomyopathy
Children exposed to tobacco smoke have worse heart function as adults
Transgender people have unaddressed heart disease risks
Intensive blood pressure lowering benefits older adults
Longer chest compression pause worsens outcomes after paediatric IHCA
Related Articles
February 18, 2021
Finerenone lowers CV events in diabetic CKD patients
February 17, 2021
No CV benefit from omega 3 in high-risk patients
February 18, 2021
Transgender people have unaddressed heart disease risks
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com